#United States #Florida Cancer Specialists #Fort Myers #Medical Director #Amanda Olson

Florida Cancer Specialists Welcomes New Late-Phase Medical Director

Florida Cancer Specialists & Research Institute, based out of Fort Myers, Florida, is thrilled to announce the appointment of Dr. Amanda Olson as the new Medical Director of Late-Phase Research, effective from July 15, 2026. Dr. Olson’s addition to the team is a significant step in the organization’s ongoing commitment to expand innovative cancer care options and increase patient access to state-of-the-art clinical trials.

Dr. Olson, a nationally renowned physician-scientist, holds board certifications in hematology and internal medicine. She has a rich background in stem cell transplantation and blood cancer treatment, specializing in various advanced therapies. Her notable areas of expertise include CAR-T therapy, cellular immunotherapy, and regenerative medicine, establishing her as a leader in this field.

With a robust track record, Dr. Olson has been the principal investigator in numerous clinical trials that assess innovative cellular therapies. She has authored over 100 peer-reviewed publications and has presented her findings at prestigious national and international conferences. Her medical degree was awarded by the Medical College of Georgia, followed by an internship and residency at Baylor College of Medicine. She also completed a fellowship in hematology and oncology at the renowned Memorial Sloan Kettering Cancer Center.

Before joining FCS, Dr. Olson contributed her expertise at MD Anderson Cancer Center, where she took on multiple roles that focused on advancing cellular therapy and transplantation research. Her membership in prominent organizations such as the American Society of Clinical Oncology, American Society of Hematology, and the International Society for Cellular Therapy further emphasizes her commitment to the field.

David Wenk, MD, assistant managing physician at FCS, expressed enthusiasm about Dr. Olson's appointment, highlighting her dedication to excellence in both patient care and scientific inquiry. Ryan Ciarrocchi, CEO of FCS, reiterated the organization’s focus on enhancing clinical research capabilities, stating that this commitment is pivotal in offering new hope and improving treatment outcomes for cancer patients.

Under Dr. Olson's leadership, FCS aims to strengthen its mission to provide world-class cancer care while expanding access to innovative therapies close to home. The institute currently oversees more than 150 clinical trials across its 30 clinics and two Drug Development Units in Florida.

The late-phase trials specifically target the monitoring and evaluation of new therapies and drugs in comparison to existing treatments for various cancer types. These clinical research initiatives play a crucial role in advancing cancer care standards, fostering hope for numerous patients across Florida.

Florida Cancer Specialists has been a transformative force in the oncology landscape for over 40 years, championing innovation and providing patients with access to a myriad of clinical trials and advanced treatment options. Its partnership with the Sarah Cannon Research Institute, along with an advanced clinical trial matching technology, positions FCS effectively at the leading edge of cancer research and treatment.

In conclusion, Dr. Olson’s expertise and dedication are set to enhance FCS's impact in cancer care. Her role will be instrumental in ensuring that patients not only receive cutting-edge treatments but also take part in shaping the future of cancer therapy through ongoing research efforts. As FCS continues its mission of offering comprehensive care, patients can anticipate further advancements in their treatment journeys, ensuring they stay at the forefront of innovative cancer therapies.